Cargando…
IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
Primary intracranial malignant melanoma (PIMM) is an uncommon cancer in childhood, that accounts for approximately 1% of melanoma, and 0.07% of brain tumors even in all age group. Because extracranial malignant melanoma usually occurs as a cutaneous lesion, affected patients have a chance to receive...
Autores principales: | Oba, Utako, Koga, Yuhki, Kawaguchi, Riichiro, Nakashima, Kentaro, Akagi, Yojiro, Hata, Nobuhiro, Yamamoto, Nanae, Kohashi, Kenichi, Masuda, Satohiro, Iihara, Koji, Oda, Yoshinao, Ohga, Shouichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715568/ http://dx.doi.org/10.1093/neuonc/noaa222.365 |
Ejemplares similares
-
IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020) -
IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY
por: Puigdelloses, Montserrat, et al.
Publicado: (2021) -
IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022) -
IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022) -
Malignant transformation of phosphaturic mesenchymal tumor: a case report and
literature review
por: Oyama, Noriko, et al.
Publicado: (2020)